



Imperial College
London

Understanding metabolic disease with modern genomics


Shedding light on the dark side of the human genome

Dr Inês Cebola

Academy of Medical Sciences Springboard Fellow

14th September 2020, Parliamentary & Scientific Committee

The human genome, genes are just the tip of the iceberg!



□ Coding sequence (<2%)


Non-coding sequence (>98%)



Transcriptional enhancers act as molecular switches to **fine tune** the expression of genes.

Coupling of biochemical assays with DNA sequencing

allows the identification of active enhancers at genome scale



Sequence variation in enhancers contributes to
a wide range of **human diseases**




Non-syndromic pancreatic agenesis


- Extremely rare condition resulting from impaired formation of the pancreas during embryonic development
- Insulin dependent neonatal diabetes
- Lack of extra-pancreatic features
- Sequencing of all coding genes in the genome did not reveal any pathogenic mutations

From whole genome sequencing to causal mutations




Prof Andrew Hattersley
Prof Sian Ellard
Dr Mike Weedon
Dr Sarah Flanagan






Regulatory element maps in **disease-relevant** tissues are essential for appropriate interpretation of noncoding pathogenic variants.

Enhancer mutations are the **most common cause** of isolated pancreatic adenocarcinoma



Weedon*, Cebola* et al. *Nature Genetics* 2014


Not all DNA variants are the same for disease risk



our risk of developing type 2 diabetes




Cases




ACTGA TACG
 ACTGA CACG
 ACTGA CACG
 ACTGA CACG
 ACTGA CACG
 ACTGA CACG
 ACTGA CACG
 ACTGA CACG
 ACTGA CACG



Controls



ACTGA TACG
 ACTGA TACG
 ACTGA TACG
 ACTGA TACG
 ACTGA TACG
 ACTGA TACG
 ACTGA TACG
 ACTGA TACG
 ACTGA TACG





Mahajan et al. *Nature Genetics* 2018

Type 2 diabetes results from alterations in multiple cell types and organs

type 2 diabetes results from alterations in multiple cell types and organs


Pancreatic islets:
where insulin
production occurs






The human genome in 3D


.....



Yijun Ruan, Jackson Lab



3D genome interactions in human pancreatic islets




pcHi-C: Promoter capture Hi-C


Collaboration with Peter Fraser's team (Babraham Institute, Cambridge)



Assignment of diabetes enhancers to target genes



Dr Irene Miguel-Escalada



Miguel-Escalada*, Bonas-Guarch*, Cebola* et al. *Nature Genetics* 2019



Enhancer hubs

Highly connected structures that regulate islet-specific expression



Joan Ponsa

Highly connected structures that regulate islet-specific expression

Enhancer hubs (n=1,318)



	Top functional annotations of hub genes	Adj. P-value	Examples
dbGaP	Diabetes Mellitus, type 2	6.1×10^{-7}	JAZF1, GLIS3, PCSK1, ZFAND3
KEGG	Insulin secretion	2.3×10^{-6}	ABCC8, KCNJ11, STX1A, SNAP25
	Circadian entrainment	2.8×10^{-6}	RYR2, PER1, CACNA1D, CAMK2B
	Maturity onset diabetes of the young	2.8×10^{-6}	NEUROD1, PDX1, MAFA, NKX2-2
Reactome	PDCL and TRIC in G-protein beta folding	3.8×10^{-4}	RGS7, GNAZ, GNAI2
	Regulation of insulin secretion	2.3×10^{-4}	FFAR1, ADR2A, STX1A, GOK
Gene Ontology	Phosphorylation of RNA polymerase II	1.8×10^{-6}	MX1, HIPK2, CDK4, FOXO3
	Negative regulation of transcription	1.2×10^{-6}	INSM1, PAX6, DACH1
	Positive regulation of transcription	3.2×10^{-6}	RFXB, FOXO1, FOXA2, PDX1
OMIM	Diabetes mellitus, type 2	0.35	TCF7L2, SLC30A8, WFS1



● Class I enhancers ● Class III enhancers ● Enhancers > 200nm
● Class II enhancers ● ISL1 and H1-LINC57 promoters


Collaboration with Marc Martí-Renom team (CRG, Barcelona)

Hubs contain common variants that affect islet function






Dr Silvia Bonàs-Guarch



What looking the islet 3D genome has taught us



- Genes important for **insulin production** in the pancreas are controlled by distinct 3D genomic domains (“**enhancer hubs**”).
- **DNA sequence variation in enhancer hubs** affects insulin production, and plays a major role in the **genetic risk of developing type 2 diabetes**.
- Noncoding diabetes risk variants may alter the expression of multiple genes, this may imply **multiple disease effector genes...**

Anderson & Sandelin Nat Rev Genet 2019

Moving forward

Biological insight



GWAS

Functional profiling
(enhancer maps)

Chromatin interactions

CRISPR/Cas9 perturbations


Candidate variants and
effector genes/transcripts



Hubs variants are predictive of onset of diabetes




Dr Silvia Bonàs-Guarch



Miguel-Escalada*, Bonas-Guarch*, Cebola* et al. *Nature Genetics* 2019

Tissue-specific polygenic risk scores can help stratify patients who

develop diabetes through different mechanisms




- β -cell polygenic risk
- β -cell dysfunction
- Younger age of onset & slimmer

- Non β -cell polygenic risk
- Insulin resistance
- Younger, overweight

- Non β -cell polygenic risk
- Insulin resistance
- Older, overweight

Islet enhancer hub risk score

Therapeutic or preventive intervention



Acknowledgements

**Imperial College
London**

Prof Peter Fraser (Babraham Institute, Cambridge)
Dr Rina Laviola

Prof Jorge Ferrer

Dr Santiago Rodriguez
Dr Irene Miguel-Escalada
Dr Silvia Bonas-Guarch
Dr Joan Ponsà

Neonatal diabetes centre (Exeter)

Prof Andrew Hattersley
Prof Sian Ellard
Dr Mike Weedon
Dr Sarah Flanagan

Prof Marc Marti-Renon (CRG, Barcelona)

Dr Irene Farabella
Julen Mendeta

Prof Inga Prokopenko (University of Surrey)

Prof Torben Hansen (University of Copenhagen)

Human Islet centres (Geneva, Milano, Lille, Charlottesville)

Dr Thierry Berney
Dr Domenico Bosco
Dr Rita Nano
Dr Lorenzo Piemonti
Prof Francois Pattou
Dr Julie Kerr-Conte
Dr Ken Brayman

wellcometrust

ciberdem
Centro de Investigación Biomédica en Red de
Diabetes y Enfermedades Metabólicas Asociadas

